and Interpreting Results This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed jour ID: 721002
Download Presentation The PPT/PDF document "Mutations and AML: Sampling, Assays," is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Mutations and AML:Sampling, Assays, and Interpreting ResultsSlide2
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Slide3
WHO Classification of AML2016 Revision Slide4
2017 CAP/ASH Guidelines Initial Workup of Acute LeukemiaSlide5
Examples of Clinically Relevant Gene MutationsSlide6
2017 CAP/ASH Cytogenetic and Mutational Analysis Guidelines: Initial WorkupSlide7
FLT3 Mutations in AMLSlide8
2017 ELN Guidelines Recommended Genetic AnalysesSlide9
c-KIT Mutation Testing for CBF-AMLSlide10
New Drugs for the Treatment of AMLSlide11
7 + 3/Midostaurin vs 7 + 3/Placebo inND FLT3-Mutated AMLSlide12
Chemotherapy +/− MidostaurinCALGB 10603/RATIFY ResultsSlide13
Enasidenib: IDH2-Mutated R/R AMLSlide14
Daunorubicin/Cytarabine Liposome (CPX-351) vs 7 + 3 in Older ND High-Risk AMLSlide15
Gemtuzumab OzogamicinSlide16
Newly Approved Agents: AML 2017Slide17
Companion Diagnostic TestsSlide18
IDH2 Testing for Enasidenib TreatmentSlide19
t-AMLEstablishing the DiagnosisSlide20
MRCsEstablishing the DiagnosisSlide21
When to Conduct Mutation AnalysisSlide22
NPM1 as Marker of Residual DiseaseSlide23
Clonal HematopoiesisSlide24
Molecular Genetic Testing Methods Slide25
Common Pitfalls in Molecular TestingSlide26
The Impact of Recent Changes in AMLSlide27
Future DirectionsSpliceosome MutationsSlide28
Key TakeawaysSlide29